Description

Aterocard (clopidogrel) Coated Tablets 0.075 g. №10

Ingredients

Active ingredient: Clopidogrel 0.075 g.
Other ingredients: Microcrystalline cellulose, lactose monohydrate, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, hypromellose, macrogol 6000.

Dosage

Dosage: The usual dose is one tablet daily, taken orally with or without food, or as directed by a healthcare professional.

Indications

Indications: Aterocard (clopidogrel) is indicated for the prevention of atherothrombotic events in patients with a history of recent myocardial infarction, recent stroke, or established peripheral arterial disease.

Contraindications

Contraindications: Do not use Aterocard (clopidogrel) if you are allergic to clopidogrel or any other ingredients in the product. Consult your healthcare provider before use.

Directions

Directions: Swallow the tablet whole with a glass of water. Do not crush or chew the tablet. Follow the dosage instructions provided by your doctor.

Scientific Evidence

Clopidogrel, the active ingredient in Aterocard, is a platelet aggregation inhibitor that works by irreversibly binding to the P2Y12 receptor on platelets, preventing ADP-mediated platelet activation and aggregation. Several clinical trials have demonstrated the efficacy of clopidogrel in reducing the risk of cardiovascular events in high-risk patients. The landmark CAPRIE trial showed a significant reduction in the combined risk of myocardial infarction, stroke, or cardiovascular death with clopidogrel compared to aspirin.

Additional Information

It is important to inform your healthcare provider about all medications, supplements, and medical conditions before starting Aterocard (clopidogrel) to prevent potential drug interactions or adverse effects. In case of any unusual bleeding, bruising, or signs of a severe allergic reaction, seek immediate medical attention.

Pharmacological Effects

Clopidogrel exerts its pharmacological effects by inhibiting platelet aggregation, thereby reducing the risk of blood clot formation in arteries. This antiplatelet action is crucial in preventing atherothrombotic events such as heart attacks and strokes. By targeting the P2Y12 receptor, clopidogrel interferes with the ADP-mediated activation of platelets, ultimately leading to decreased platelet aggregation and improved blood flow.

Clinical Trials and Comparative Effectiveness

Numerous clinical trials have established the efficacy of clopidogrel in reducing the incidence of cardiovascular events in patients with atherosclerosis and a history of cardiovascular diseases. Comparative studies have shown clopidogrel to be as effective as or even superior to other antiplatelet agents in certain patient populations. For example, the COMMIT trial demonstrated that clopidogrel reduced the risk of major cardiovascular events in patients with acute myocardial infarction when added to standard therapy.

Overall, Aterocard (clopidogrel) coated tablets 0.075 g. №10 offer a well-established and effective treatment option for individuals at risk of atherothrombotic events, backed by substantial scientific evidence and clinical data.